Sooma Medical—the company behind the Sooma tDCS Therapy Kits—has just secured a US patent for its new tDCS electrode.
The electrode was developed to essentially be superior to other market tDCS electrodes in terms of decreased resistance at skin-electrode interface, decreased time for electrode preparation, and increased stimulation dosage accuracy. The electrode can also stay on the skin longer than other market tDCS electrodes while maintaining a stable connection quality.
This new electrode further reinforces the incremental trend we are seeing in tDCS toward safer and easier-to-use solutions in tDCS delivery.
Sooma products—along with the new tDCS electrode—are distributed in over 30 different countries. For those in the US, the Sooma system is sold under Caputron.
Sources:
